Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Biotechnical Methods Section BTS
  • Published:

Biotechnical Methods Section (BTS)

Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma

Leukemia volume 19, pages 275–278 (2005)Cite this article

Abstract

Ploidy appears as an important parameter in both the biology and the clinical evolution of multiple myeloma. However, its evaluation requires either a successful karyotyping (obtained in 30% of the patients) or a DNA index calculation by flow cytometry (not routinely performed in myeloma). We validated a novel method based on interphase fluorescence in situ hybridization that can be utilitized to analyze almost all the patients. The method was very specific and sensitive for the detection of hyperdiploidy. Extended studies showed that most recurrent 14q32 translocations occur in nonhyperdiploid clones, and that deletions of chromosome 13 were less frequently observed in hyperdiploid clones (48 vs 66%). Further large studies are ongoing to evaluate the prognostic value of ploidy in myeloma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Dewald GW, Kyle RA, Hicks GA, Greipp PR . The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 1985; 66: 380–390.

    CAS  PubMed  Google Scholar 

  2. Gould J, Alexanian R, Goodacre A, Pathak S, Hecht B, Barlogie B . Plasma cell karyotype in multiple myeloma. Blood 1988; 71: 453–456.

    CAS  PubMed  Google Scholar 

  3. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletion of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86: 4250–4256.

    CAS  PubMed  Google Scholar 

  4. Laï JL, Zandecki M, Mary JY, Bernardi F, Izydorczyk V, Flactif M et al. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood 1995; 85: 2490–2497.

    PubMed  Google Scholar 

  5. Sawyer JR, Waldron JA, Jagannath S, Barlogie B . Cytogenetic finding in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995; 82: 41–49.

    Article  CAS  PubMed  Google Scholar 

  6. Fonseca R, Coignet LJA, Dewald GW . Cytogenetic abnormalities in multiple myeloma. Hematol/Oncol Clin N Am 1999; 13: 1169–1180.

    Article  CAS  Google Scholar 

  7. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C . Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001; 98: 2229–2238.

    Article  CAS  PubMed  Google Scholar 

  8. Calasanz MJ, Cigudosa JC, Odero MD, Garcia-Foncillas J, Marin J, Ardanaz MT et al. Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma. Br J Haematol 1997; 98: 418–425.

    Article  CAS  PubMed  Google Scholar 

  9. Fassas ABT, Spencer T, Sawyer J, Zangari M, Lee CL, Anaissie E et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 2002; 118: 1041–1047.

    Article  CAS  PubMed  Google Scholar 

  10. Debes-Marun CS, Dewald GW, Bryant S, Picken E, Santana-Davila R, Gonzalez-Paz N et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003; 17: 427–436.

    Article  CAS  PubMed  Google Scholar 

  11. Latreille J, Barlogie B, Dosik G, Johnston DA, Drewinko B, Alexanian R . Cellular DNA content as a marker of human multiple myeloma. Blood 1980; 55: 403–408.

    CAS  PubMed  Google Scholar 

  12. Barlogie B, Alexanian R, Dixon D, Smith L, Smallwood L, Delasalle K . Prognostic implications of tumor cell DNA and RNA content in multiple myeloma. Blood 1985; 66: 338–341.

    CAS  PubMed  Google Scholar 

  13. Tienhaara A, Pelliniemi TT . Flow cytometric DNA analysis and clinical correlations in multiple myeloma. Am J Clin Pathol 1992; 97: 322–330.

    Article  CAS  PubMed  Google Scholar 

  14. Smadja NV, Louvet C, Isnard F, Dutel JL, Grange MJ, Varette C et al. Cytogenetic study in multiple myeloma at diagnosis: comparison of two techniques. Br J Haematol 1995; 90: 619–624.

    Article  CAS  PubMed  Google Scholar 

  15. Brigaudeau C, Trimoreau F, Gachard N, Rouzier E, Jaccard A, Bordessoule D et al. Cytogenetic study of 30 patients with multiple myeloma: comparison of 3 and 6 day bone marrow cultures stimulated or not with cytokines by using a miniaturized karyotypic method. Br J Haematol 1997; 96: 594–600.

    Article  CAS  PubMed  Google Scholar 

  16. Hernandez JM, Gutierrez NC, Almeida J, Garcia JL, Sanchez MA, Mateo G et al. IL-4 improves the detection of cytogenetic abnormalities in multiple myeloma and increases the proportion of clonally abnormal metaphases. Br J Haematol 1998; 103: 163–167.

    Article  CAS  PubMed  Google Scholar 

  17. Seong C, Delasalle K, Hayes K, Weber D, Dimopoulos D, Swantkowski J et al. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol 1998; 101: 189–194.

    Article  CAS  PubMed  Google Scholar 

  18. Smadja NV, Fruchart C, Isnard F, Louvet C, Dutel JL, Cheron N et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia 1998; 12: 960–969.

    Article  CAS  PubMed  Google Scholar 

  19. Rajkumar SV, Fonseca R, Dewald GW, Therneau TM, Lacy MQ, Kyle RA et al. Cytogenetic abnormalities correlate with the plasma cell labelling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet 1999; 113: 73–77.

    Article  CAS  PubMed  Google Scholar 

  20. Shankey TV, Rabinovitch PS, Bagwell B, Bauer KD, Duque RE, Hedley DW et al. Guidelines for implementation of clinical DNA cytometry. Cytometry 1993; 14: 472–477.

    Article  CAS  PubMed  Google Scholar 

  21. Avet-Loiseau H, Li JY, Facon T, Brigaudeau C, Morineau N, Maloisel F et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 1998; 58: 5640–5645.

    CAS  PubMed  Google Scholar 

  22. Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, for the Intergroupe Francophone du Myelome et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features and clinical presentation. Blood 2002; 99: 2185–2191.

    Article  CAS  PubMed  Google Scholar 

  23. Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 2002; 99: 3735–3741.

    Article  CAS  PubMed  Google Scholar 

  24. Fonseca R, Debes-Marun CS, Picken EB, Dewald GW, Bryant SC, Winkler JM et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 2003; 102: 2562–2567.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study has been supported by a grant from the Ligue contre le Cancer, and by a Programme Hospitalier de Recherche Clinique.

Author information

Authors and Affiliations

  1. Laboratory of Hematology, University Hospital, Nantes, France

    S Wuilleme, N Robillard, L Lodé, F Magrangeas, S Minvielle & H Avet-Loiseau

  2. Vysis Inc., Downers Grove, IL, USA

    H Beris & J Proffitt

  3. Clinical Hematology Department, University Hospital, Nantes, France

    J-L Harousseau

Authors
  1. S Wuilleme
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Robillard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Lodé
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F Magrangeas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Beris
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J-L Harousseau
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Proffitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Minvielle
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H Avet-Loiseau
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the Intergroupe Francophone du Myélome

Corresponding author

Correspondence to H Avet-Loiseau.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wuilleme, S., Robillard, N., Lodé, L. et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia 19, 275–278 (2005). https://doi.org/10.1038/sj.leu.2403586

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403586

Keywords

This article is cited by

Search

Advanced search

Quick links